share_log

万泰生物(603392.SH):九价宫颈癌疫苗二期扩产建设项目按计划进行中,已完成主要设备采购及车间净化装修

Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The second-phase expansion project of the nine-valent cervical cancer vaccine is progressing as planned, with the main equipment procurement and workshop purification renovation completed.

Gelonghui Finance ·  Nov 7, 2024 16:45

Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the Phase II expansion project of the nine-valent cervical cancer vaccine is progressing as planned. The main equipment procurement and workshop purification renovation have been completed, and equipment commissioning and validation are underway. In addition to the flagship product, the nine-valent HPV vaccine, other research and development projects of the company are progressing orderly.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment